A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
暂无分享,去创建一个
Tae-You Kim | Y. Chao | C. Yen | A. Cheng | D. Lin | B. Ryoo | Yin-Hsun Feng | D. Huang | D. Schnell | J. Hocke | A. Loembé
[1] T. Meyer,et al. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[2] T. Meyer,et al. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib. , 2016 .
[3] R. Finn,et al. Systemic therapy in HCC: lessons from brivanib. , 2014, Journal of hepatology.
[4] L. Roberts,et al. Fibroblast growth factor signaling in liver carcinogenesis , 2014, Hepatology.
[5] Rolf Kaiser,et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.
[6] G. Malaguarnera,et al. Systemic therapies in hepatocellular carcinoma: present and future. , 2013, Future oncology.
[7] G. Abou-Alfa,et al. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? , 2013, The Lancet. Oncology.
[8] J. Llovet,et al. Impact of intra‐individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma , 2012, Hepatology.
[9] W. Yeo,et al. Targeted therapy of hepatocellular carcinoma: Present and future , 2012, Journal of gastroenterology and hepatology.
[10] H. El‐Serag,et al. Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.
[11] H. Earl,et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Sahani,et al. HCC and angiogenesis: possible targets and future directions , 2011, Nature Reviews Clinical Oncology.
[13] R. Kaiser,et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[14] M. Kudo,et al. Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo , 2010, Clinical Cancer Research.
[15] J. Furuse,et al. Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma , 2010, BMC Cancer.
[16] J. Furuse,et al. Issues and controversies of hepatocellular carcinoma‐targeted therapy clinical trials in Asia: experts' opinion , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[17] A. Zhu,et al. The role of signaling pathways in the development and treatment of hepatocellular carcinoma , 2010, Oncogene.
[18] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[19] Jin-Lin Hou,et al. Hepatocellular carcinoma in the Asia pacific region , 2009, Journal of gastroenterology and hepatology.
[20] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[21] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[22] W. Sommergruber,et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.
[23] J. Dufour,et al. Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.
[24] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.